CD80 anticorps

N° du produit ABIN969028

Détail du produit anti-CD80 anticorps

Antigène: CD80

Reactivité: Humain

Hôte: Souris

Clonalité: Monoclonal

Conjugué: Cet anticorp CD80 est non-conjugé

Application: ELISA, Immunohistochemistry (IHC), Immunocytochemistry (ICC)

Purification: purified

Immunogène: Purified recombinant fragment of CD80 expressed in E. coli.

Clone: 2A2

Isotype: IgG1

Information d'application

Indications d'application: ELISA: 1:10000, IHC: 1:200 - 1:1000, ICC: 1:200 - 1:1000

Restrictions: For Research Use only

Stockage

Format: Liquid

Buffer: Ascitic fluid containing 0.03 % sodium azide.

Agent conservateur: Sodium azide

Précaution d'utilisation: This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Stock: 4 °C/-20 °C

Stockage commentaire: 4°C, -20°C for long term storage

Références pour anticorps anti-CD80 (ABIN969028)

Wang, Liu, Wu, Zhu, Wang, Xu: "Evaluation of CD86/CD28 and CD40/CD154 pathways in regulating monocyte-derived CD80 expression during their interaction with allogeneic endothelium." dans: Transplantation proceedings, Vol. 40, Issue 8, pp. 2729-33, (2008) (PubMed).

Stephan, Ponomarev, Brentjens, Chang, Dobrenkov, Heller, Sadelain: "T cell-encoded CD80 and 4-1BBL induce auto- and transcostimulation, resulting in potent tumor rejection." dans: Nature medicine, Vol. 13, Issue 12, pp. 1440-9, (2007) (PubMed).

Détails sur CD80

Antigène: CD80

Autre désignation: CD80 (CD80 Produits)

Synonymes: anticorps B7, anticorps B7-1, anticorps B7.1, anticorps BB1, anticorps CD28LG, anticorps CD28LG1, anticorps LAB7, anticorps B71, anticorps Cd28l, anticorps Ly-53, anticorps Ly53, anticorps MIC17, anticorps TSA1, anticorps CD80 molecule, anticorps Cd80 molecule, anticorps CD80 antigen, anticorps CD80, anticorps Cd80

Sujet:

Description: The protein CD80 (Cluster of Differentiation 80) is a molecule found on activated B cells and monocytes which provides a costimulatory signal necessary for T cell activation and survival. It is also known as B7.1. Its principal mode of action is by binding to CD28. Along with CD86, these molecules provide the necessary stimuli to prime T cells against antigens presented by antigen-presenting cells. CD80 and CD86 also bind to CTLA-4, a cell surface molecule expressed on activated T cells. Interactions between CD80 or CD86 with CTLA-4 decrease the response of T cells. Mouse research by scientists at Emory University showed that estrogen-related bone loss is linked to recently discovered pathways involving various proteins, such as CD80 and other functions. In a nutshell, reactive oxygen stimulates dendritic cells, which activate other immune cells to up-regulate production of CD80, the molecule co-responsible for T cell activation. "When this pathway is activated, it leads to increased T cell TNF production and ultimately to bone loss." In turn, T cells produce a protein, Tumor Necrosis Factor, which increases the formation of osteoclasts in rodents and humans. Osteoclasts cause minerals to be released from the bone, so that calcium is taken into the bloodstream to be used for other functions of the body. Osteoclast differentiation is inhibited by osteoprotegerin, Estrogen stimulates osteoprotegerin production.

Aliases: CD28LG, LAB7, B7.1

Poids moléculaire: 55 kDa

ID gène: 941

HGNC: 941

Pathways: TCR Signaling, Fc-epsilon Receptor Signaling Pathway, EGFR Signaling Pathway, Neurotrophin Signaling Pathway, Positive Regulation of Immune Effector Process, Cancer Immune Checkpoints